Judy A. Tjoe

Judy A. Tjoe

General Surgery

1506 S Oneida St
Appleton, WI 54915

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 20, 2026

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

Journal: International journal of radiation oncology, biology, physics

Published: March 09, 2026

Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.

Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.

Journal: JAMA surgery

Published: May 07, 2025

Nipple-Sparing Mastectomy and Adequate Margins for Patients With Ductal Carcinoma In Situ.

Nipple-Sparing Mastectomy and Adequate Margins for Patients With Ductal Carcinoma In Situ.

Journal: The American surgeon

Published: April 12, 2024

Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study.

Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study.

Journal: NPJ breast cancer

Published: September 05, 2023

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 11, 2023

Positive Nipple Margins and Oncologic Outcomes of Nipple-Sparing Mastectomy in a Large Community-Based Hospital System.

Positive Nipple Margins and Oncologic Outcomes of Nipple-Sparing Mastectomy in a Large Community-Based Hospital System.

Journal: The American surgeon

Published: February 17, 2023

Reply to I. Jatoi.

Reply to I. Jatoi.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2022

Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 23, 2021

Breast MRI in the setting of DCIS: quality trials are still needed to determine its value.

Breast MRI in the setting of DCIS: quality trials are still needed to determine its value.

Journal: European radiology

Published: March 24, 2021

Factors Associated With Breast Cancer Surgery Delay Within a Coordinated Multihospital Community Health System: When Does Surgical Delay Impact Outcome?

Factors Associated With Breast Cancer Surgery Delay Within a Coordinated Multihospital Community Health System: When Does Surgical Delay Impact Outcome?

Journal: Clinical breast cancer

Published: January 09, 2021

Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age.

Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: November 25, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026